Systemic Administration of Reovirus (Reolysin) Inhibits Growth of Human Sarcoma Xenografts

Department of Pediatric Hematology/Oncology, Phoenix Children's Hospital, Phoenix, Arizona 85016, USA.
Cancer (Impact Factor: 4.89). 04/2011; 117(8):1764-74. DOI: 10.1002/cncr.25741
Source: PubMed

ABSTRACT Despite advancement in therapies, overall survival rates for relapsed pediatric sarcomas are dismal. Newer therapies are needed to effectively salvage these patients. Oncolytic viruses (such as reovirus) and other genetically altered viruses (such as herpes simplex viruses and adenoviruses) have shown efficacy in a variety of solid tumors including sarcomas. Reolysin is an unmodified oncolytic reovirus that selectively replicates in Ras-activated cancer cells while not causing any significant human illness in its wild form.
By using a panel of pediatric sarcoma cell lines in vitro and flank xenografts in vivo, Reolysin was evaluated as a single agent and in combination with cisplatin and radiation therapy. Electron microscopy and immunohistochemistry was used to demonstrated a cytopathic effect in treated tumors.
Reolysin inhibited the proliferation and viability of sarcoma cell lines at a dose of 1 to 10 virus particles per cell. In vivo, 5 × 10(9) plaque-forming units (PFU) administered via the tail vein every other day for 3 doses every 21 days inhibited the growth of tumor xenografts with improvement in event-free survival. In the SKES1 Ewing sarcoma line, there was therapeutic enhancement when reovirus was administered in combination with radiation or cisplatin. In the RH30 line and the OS33 line, therapeutic enhancement was demonstrated with radiation and cisplatin, respectively.
These results suggest that Reolysin alone or in combination with other cytotoxic agents may be effective therapy in pediatric sarcomas.

Download full-text


Available from: Chandan Guha, Dec 15, 2014
21 Reads
  • Source
    • "MRV is an oncolytic virus that preferentially replicates in tumor cells over normal cells [21]. Successful demonstration of MRV oncolytic activity against numerous cancer types in animal models [22–24] led to its development and clinical testing as a cancer therapy in a number of Phase I/II/III human clinical trials. It has emerged as a safe and effective therapy for a number of cancer types leading to disease stabilization and tumor regression in many patients [25–28]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hypoxia has emerged as one of the most important drivers of tumor aggression, metastasis, and poor clinical outcome in many cancers.In prostate cancer (PCa), hypoxia has been strongly correlated to biochemical failure and local recurrence. However, current PCa treatment options do not address hypoxic cells highlighting a critical gap in existing therapies and the need for development of therapies that target hypoxic prostate tumor cells. Mammalian orthoreovirus (MRV) is an oncolytic virus that targets tumor cells over normal cells which has been shown to be safe and effective against many cancers in vitro, in animal models, and in human clinical trials. We found that MRVinfects and replicates in hypoxic prostate tumor cells to levels comparable to normoxic cells leading to apoptosis and cell death. In addition, the regulatory subunit (HIF-1α) of the master transcriptional regulator of hypoxia, HIF-1, was significantly downregulated in infected cells. HIF-1α downregulation was found to occur via ubiquitin-dependent proteasome-mediated degradation and translational inhibition. Virus-mediated HIF-1α degradation required the HIF-1α PAS domain and expression of the receptor for activated kinase C (RACK1) protein. These data provide evidence that MRV may be a viable therapeutic option for targeting hypoxic cells and HIF-1α in PCa.
    Oncotarget 01/2014; 5(2):561-574. DOI:10.18632/oncotarget.1767 · 6.36 Impact Factor
  • Source
    • "Not only was survival significantly increased in an in vivo mouse model, but spinal and leptomeningeal metastases, which are relatively common in MDB patients, were decreased with intrathecal injections of the virus. Using the same strain of virus, Hingorani et al. demonstrated efficacy of reovirus delivered systemically to treat rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma cell lines in the flank of athymic nude mice (55). Combining the virus with radiation or cisplatin enhanced the therapeutic effect. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Cancer stem cells (CSCs), also termed "cancer-initiating cells" or "cancer progenitor cells," which have the ability to self-renew, proliferate, and maintain the neoplastic clone, have recently been discovered in a wide variety of pediatric tumors. These CSCs are thought to be responsible for tumorigenesis and tumor maintenance, aggressiveness, and recurrence due to inherent resistance to current treatment modalities such as chemotherapy and radiation. Oncolytic virotherapy offers a novel, targeted approach for eradicating pediatric CSCs using mechanisms of cell killing that differ from conventional therapies. Moreover, oncolytic viruses have the ability to target specific features of CSCs such as cell-surface proteins, transcription factors, and the CSC microenvironment. Through genetic engineering, a wide variety of foreign genes may be expressed by oncolytic viruses to augment the oncolytic effect. We review the current data regarding the ability of several types of oncolytic viruses (herpes simplex virus-1, adenovirus, reovirus, Seneca Valley virus, vaccinia virus, Newcastle disease virus, myxoma virus, vesicular stomatitis virus) to target and kill both CSCs and tumor cells in pediatric tumors. We highlight advantages and limitations of each virus and potential ways in which next-generation engineered viruses may target resilient CSCs.
    Pediatric Research 04/2012; 71(4 Pt 2):500-10. DOI:10.1038/pr.2011.58 · 2.31 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: dětské onkologie Lékařské fakulty Masarykovy univerzity a Fakultní nemocnice, Brno Konvenční léčba sarkomů skeletu je relativně úspěšná, trvalého vyléčení dosáhne 60 – 70 % pacientů. Přes tyto úspěchy (historicky přežívalo 15 – 20 % pacientů) není posledních dvacet let znatelný principiální posun v léčbě. Cílená terapie je jednou z možných cest, kterou lze dát šanci na přežití pacientům s relapsy nebo rezistentními nádory, nebo snížit toxicitu konvenční léčby. V článku je souhrnně popsán stav výzkumu nových léčebných možností u sarkomů skeletu. Většina léků je ve fázi 1. a 2. klinického zkoušení. Klíčová slova: sarkom skeletu, cílená terapie, angiogeneze, inhibitor proteinkinázy. Targeted therapics for bone sarcomas Therapy success in bone sarcoma is significantly better compared to history cohorts with 60 – 70 % overall survival to date. Unfortunately, there is yet no shift and movement in better survival of patients with relapsed and refractory bone sarcomas during last twenty years. This article reviews targeted therapeutics for bone sarcomas which are under investigation and which could give chance to patients suffering from relapsed and chemoresistant bone sarcomas. Majority of the targeted drugs are given as part of phase 1 or 2 studies.
Show more